ClinicalTrialStartPulse: Phase 2, page 4 of 4
Records 351 to 500 of the 500 newest listed for this hub. Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
| Record | Phase | Conditions | Enrollment |
|---|---|---|---|
| National Cancer Institute (NCI) | Phase 2 | NSCLC; Non-Small Cell Lung Cancer; Lung Cancer; Prostate Cancer; Thymic Epithelial Tumors; TETs | 67 |
| Sun Yat-sen University | Phase 2 | Nasopharyngeal Carcinoma (NPC) | 30 |
| University of Nebraska | Phase 2 | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | 56 |
| University of Washington | Phase 2 | Anxiety; Depression; Hematopoietic and Lymphatic System Neoplasm; Metastatic Malignant Solid Neoplasm | 16 |
| Fox Chase Cancer Center | Phase 2 | Metastatic Pancreatic Cancer | 37 |
| Memorial Sloan Kettering Cancer Center | Phase 2 | Non-sclerotic Cutaneous Chronic Graft-versus-host Disease | 24 |
| Haukeland University Hospital | Phase 2 | Prostate Cancer; Prostate Cancer Locally Advanced; Prostatic Neoplams | 191 |
| Madigan Army Medical Center | Phase 2 | Dental Implant | 60 |
| Washington University School of Medicine | Phase 2 | Head and Neck (HNSCC); Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M); Head and Neck Squamous Cell Carcinoma; Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma | 40 |
| PETHEMA Foundation | Phase 2 | Multiple Myeloma Refractory; Multiple Myeloma in Relapse | 60 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Endometrial Cancer | 10 |
| National Taiwan University Hospital | Phase 2 | Hepato Cellular Carcinoma (HCC); Immune Checkpoint Inhibitor; Neoadjuvant Therapy | 40 |
| University of California, San Francisco | Phase 2 | Postoperative Recovery; Total Knee Arthroplasty | 80 |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 | Stage IV Colorectal Cancer; Curative Resection | 19 |
| Memorial Sloan Kettering Cancer Center | Phase 2 | Non Small Cell Lung Cancer; Lung Cancer; Nsclc; NSCLC Stage II; NSCLC, Stage III | 61 |
| Gruppo Oncologico del Nord-Ovest | Phase 2 | Colorectal Cancer | 16 |
| M.D. Anderson Cancer Center | Phase 2 | Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Anaplastic Large Cell Lymphoma | 38 |
| St. Petersburg State Pavlov Medical University | Phase 2 | Hodgkin Lymphoma | 37 |
| Shanghai Zhongshan Hospital | Phase 2 | Advanced Biliary Tract Cancer | 39 |
| German CLL Study Group | Phase 2 | CLL (Chronic Lymphocytic Leukemia) | 80 |
| University Hospital, Gentofte, Copenhagen | Phase 2 | Obesity & Overweight | 18 |
| Chongqing University Cancer Hospital | Phase 2 | Rectal Cancer Patients; Locally Advanced Rectal Cancer (LARC) | 100 |
| Medical College of Wisconsin | Phase 2 | Squamous Cell Carcinoma | 26 |
| Brigham and Women's Hospital | Phase 2 | Primary Sclerosing Cholangitis (PSC) | 15 |
| First Affiliated Hospital of Fujian Medical University | Phase 2 | Prostate Cancer | 25 |
| National Cancer Institute (NCI) | Phase 2 | Neurofibromatosis 1; Neurofibromatosis Type 1; NF1; Neurofibroma, Plexiform | 99 |
| University of Miami | Phase 2 | Cerebral Aneurysm | 26 |
| National Cancer Institute (NCI) | Phase 2 | DOCK8 Deficiency | 76 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 | Diabetes; Lipodystrophy; Hyperlipidemia | 29 |
| Memorial Sloan Kettering Cancer Center | Phase 2 | Pancreatic Cancer; Skin Toxicities | 122 |
| University College Cork | Phase 2 | Breast Cancer; Metastatic Breast Cancer; Locally Advanced Breast Cancer (LABC) | 50 |
| Orvida Pharma (formerly Kamari Pharma) | Phase 2 | Pachyonychia Congenita | 10 |
| Holland Bloorview Kids Rehabilitation Hospital | Phase 2 | Autism Disorder | 100 |
| Peking University Cancer Hospital & Institute | Phase 2 | Non-Small Cell Lung Cancer | 23 |
| University of Utah | Phase 2 | Erythrocytosis; Pulmonary Hypertension; Thrombosis | 16 |
| University of Virginia | Phase 2 | Thrombocytopenia | 26 |
| City of Hope Medical Center | Phase 2 | Type 1 Diabetes Mellitus | 10 |
| University of Arizona | Phase 2 | Urinary Bladder Cancer | 31 |
| National Cancer Institute (NCI) | Phase 2 | Hepatocellular Cancer; Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma | 27 |
| Memorial Sloan Kettering Cancer Center | Phase 2 | Bladder Cancer; Metastatic Bladder Cancer; Urothelial Carcinoma | 54 |
| Canadian Cancer Trials Group | Phase 2 | NSCLC | 4 |
| Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 2 | Diphtheria; Pertussis; Tetanus; Poliomyelitis; Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines | 380 |
| Fudan University | Phase 2 | Peritoneal Mesothelioma; First-line Therapy | 19 |
| National Cancer Institute (NCI) | Phase 2 | LGCMN; Large and Giant Congenital Melanocytic Nevi; NF1; Solid Tumor; Pediatric Tumors; Neurocutaneous Melanocytosis | 15 |
| University of Alberta | Phase 2 | Neuroendocrine Tumors | 50 |
| Washington University School of Medicine | Phase 2 | Extensive-stage Small Cell Lung Cancer | 6 |
| Barbara Ann Karmanos Cancer Institute | Phase 2 | Diffuse Large B-Cell Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Extranodal Marginal Zone Lymphoma; Recurrent Follicular Lymphoma; Recurrent Indolent Adult Non-Hodgkin Lymphoma; Recurrent Mantle Cell Lymphoma | 43 |
| Memorial Sloan Kettering Cancer Center | Phase 2 | Acute Myelogenous Leukemia (AML); Acute Lymphoblastic Leukemia (ALL); Chronic Myelogenous Leukemia (CML); Myelodysplastic Syndromes (MDS); Myeloproliferative Disorder; Non-Hodgkin's Lymphoma | 17 |
| First Affiliated Hospital of Fujian Medical University | Phase 2 | Prostate Cancer | 24 |
| University Health Network, Toronto | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | 48 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 | BTC | 41 |
| University of New Hampshire | Phase 2 | Alcohol Misuse Prevention; Sexual Violence Prevention | 350 |
| The First Affiliated Hospital with Nanjing Medical University | Phase 2 | PCNSL (Primary CNS Lymphoma); Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma (SCNSL) | 40 |
| Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 30 |
| Ruijin Hospital | Phase 2 | Lung Neoplasm Malignant | 64 |
| VA Office of Research and Development | Phase 2 | Metastatic Non-Small Cell Lung Cancer; Cancer-Associated Weight Loss; Elevated Inflammatory Markers | 43 |
| Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. | Phase 2 | Autoimmune Pulmonary Alveolar Proteinosis | 70 |
| Al-Azhar University | Phase 2 | Breast Cancer; Peripheral Neuropathy Due to Chemotherapy; VAS Score | 80 |
| Ruijin Hospital | Phase 2 | Poor Graft Function; Myelodysplastic Syndromes; Hematopoietic Stem Cell Transplantation | 66 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Fibrolamellar Hepatocellular Carcinoma | 6 |
| Canadian Myeloma Research Group | Phase 2 | Multiple Myeloma | 72 |
| Duke University | Phase 2 | Cancer of the Cervix; Vulvar Cancer; Esophageal Cancer; Anal Canal Cancer | 90 |
| Memorial Sloan Kettering Cancer Center | Phase 2 | Dedifferentiated Liposarcoma; Soft Tissue Sarcoma; Sarcoma,Soft Tissue; Sarcoma; Recurrent Dedifferentiated Liposarcoma; Unresectable Dedifferentiated Liposarcoma | 16 |
| National Eye Institute (NEI) | Phase 2 | ABCA4 Retinopathy; Stargardt Disease; Retinal Dystrophy; Retinal Degeneration | 55 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Acute Lymphoblastic Leukemia; B-cell Non Hodgkin Lymphoma; Pre B-Cell Acute Lymphoblastic Leukaemia | 44 |
| Centre Leon Berard | Phase 2 | Unresectable Gastrointestinal Stromal Tumor (GIST); Locally Advanced Gastrointestinal Stromal Tumor (GIST); Metastatic Gastrointestinal Stromal Tumor | 58 |
| Centre Jean Perrin | Phase 2 | Glioblastoma | 66 |
| Children's Hospital Medical Center, Cincinnati | Phase 2 | Solid Organ Transplant; Viral Infection | 42 |
| Sanofi | Phase 2 | Colitis Ulcerative | 170 |
| Acurx Pharmaceuticals Inc. | Phase 2 | Clostridium Difficile Infection Recurrence | 20 |
| Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Metastatic Breast Cancer | 87 |
| Sanofi | Phase 2 | Crohn's Disease | 105 |
| YolTech Therapeutics Co., Ltd | Phase 2 | Primary Hyperoxaluria Type 1; PH1 | 36 |
| Iovance Biotherapeutics, Inc. | Phase 2 | Sarcoma; Soft Tissue Sarcoma (STS); Advanced Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Dedifferentiated Liposarcoma (DDLPS) | 80 |
| Korro Bio, Inc. | Phase 2 | Urea Cycle Disorders, Inborn; Urea Cycle Disorders; Ornithine Transcarbamylase (OTC) Deficiency; Arginase 1 Deficiency; NAGS Deficiency; Carbamylphosphate Synthetase I | 30 |
| Merck Sharp & Dohme LLC | Phase 2 | Pulmonary Arterial Hypertension | 6 |
| Ono Pharmaceutical Co., Ltd. | Phase 2 | Pediatric Malignant Solid Tumor and Epithelioid Sarcoma | 50 |
| Sanofi | Phase 2 | Asthma | 335 |
| Keros Therapeutics, Inc. | Phase 2 | Duchenne Muscular Dystrophy | 36 |
| Qilu Pharmaceutical Co., Ltd. | Phase 2 | Cancer Cachexia; Cancer Cachexia Syndrome | 88 |
| HB BioTech, LLC | Phase 2 | Panic Disorder; Mental Illness | 170 |
| Genmab | Phase 2 | Non Small Cell Lung Cancer Metastatic | 125 |
| GlaxoSmithKline | Phase 2 | Alzheimer's Disease | 367 |
| University of Alabama at Birmingham | Phase 2 | Renal Cell Carcinoma | 22 |
| Peking University Cancer Hospital & Institute | Phase 2 | Colorectal Cancer | 20 |
| Shenzhen Geno-Immune Medical Institute | Phase 2 | Lung Cancer; NSCLC | |
| Peking Union Medical College Hospital | Phase 2 | Acquired Pure Red Cell Aplasia | |
| Centre Hospitalier de Bethune | Phase 2 | Cardiac Arrest | 65 |
| University of Utah | Phase 2 | Knee Osteoarthritis; Knee Osteoarthritis (Knee OA); Knee Osteoarthritis (OA) | |
| Oslo University Hospital | Phase 2 | Colorectal Cancer; Liver Metastases; Chemotherapy Effect | 39 |
| Imagion Biosystems, Inc. | Phase 2 | HER2-positive Breast Cancer | 70 |
| Prime Medicine, Inc. | Phase 2 | Alpha-1 Antitrypsin Deficiency; Alpha-1 Antitrypsin Deficiency-associated Lung Disease; Alpha-1 Antitrypsin Deficiency (AATD); AATD | 54 |
| IRulya Therapeutics Inc. | Phase 2 | Sarcoidosis Associated Pulmonary Hypertension | 60 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Phase 2 | Obese; Obesity; Obesity Type 2 Diabetes Mellitus; Weight Loss | 58 |
| CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 2 | Respiratory Syncytial Virus Infections | 80 |
| Verrica Pharmaceuticals Inc. | Phase 2 | Common Warts; Common Warts (Verruca Vulgaris); Human Papilloma Virus (HPV); Warts | 30 |
| EktaH | Phase 2 | Obesity / Overweight; Obesity (BMI Equal to or >30) | 31 |
| Elpiscience (Suzhou) Biopharma, Ltd. | Phase 2 | Non-Small Cell Lung Cancer | 30 |
| Alpine Immune Sciences, Inc. | Phase 2 | Lupus Nephritis; Immunoglobulin A Nephropathy; Membranous Nephropathy; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 72 |
| Defibrio, LLC | Phase 2 | VF; VT | 25 |
| Hansoh BioMedical R&D Company | Phase 2 | Moderate-to-severe Plaque Psoriasis | 390 |
| Wave Life Sciences USA, Inc. | Phase 2 | Duchenne Muscular Dystrophy | 25 |
| Hemay Pharmaceutical PTY. LTD. | Phase 2 | Safety; Efficiency | 90 |
| Antelope Surgical Solutions, Inc | Phase 2 | Prostate Cancer; Prostate Cancer (Adenocarcinoma); Fluorescence Imaging | 15 |
| H. Lundbeck A/S | Phase 2 | Cushing's Disease | 16 |
| argenx | Phase 2 | Systemic Sclerosis (SSc) | 87 |
| Xentria, Inc. | Phase 2 | Pulmonary Sarcoidosis | 31 |
| AbelZeta Inc. | Phase 2 | Large B Cell Lymphoma; LBCL; Diffuse Large B Cell Lymphoma (DLBCL); Relapse Diffuse Large B Cell Lymphoma; High Grade B Cell Lymphoma; FL | 55 |
| Solid Biosciences Inc. | Phase 2 | Duchenne Muscular Dystrophy | 12 |
| Hoffmann-La Roche | Phase 2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | 51 |
| Full-Life Technologies UK Limited | Phase 2 | Solid Tumor; NSCLC; Colorectal Cancer; Head and Neck Cancer; Cholangiocarcinoma | 208 |
| GE Healthcare | Phase 2 | Cognitive Dysfunction | 20 |
| Bristol-Myers Squibb | Phase 2 | Early-Stage Non-Small Cell Lung Cancer | 80 |
| Satellos Bioscience, Inc. | Phase 2 | Facioscapulohumeral Muscular Dystrophy (FSHD) | 51 |
| Graviton Bioscience Corporation | Phase 2 | Friedreich's Ataxia | 48 |
| Telix Pharmaceuticals (Innovations) Pty Limited | Phase 2 | ccRCC; Renal Cell Carcinoma (Kidney Cancer); Renal Cell Carcinoma (RCC); Renal Cell Cancer Metastatic; Renal Cell Cancer, Recurrent; Clear Cell Renal Cell Cancer (ccRCC) | 40 |
| GI Innovation, Inc. | Phase 2 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 107 |
| AbbVie | Phase 2 | Upper Facial Lines; Glabellar Lines | 300 |
| Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. | Phase 2 | Enteric Hyperoxaluria | 30 |
| TransThera Sciences (Nanjing), Inc. | Phase 2 | Prostate Cancer (CRPC) | 182 |
| Shandong Suncadia Medicine Co., Ltd. | Phase 2 | Primary Aldosteronism | 61 |
| Pfizer | Phase 2 | Breast Cancer; Breast Neoplasms | 74 |
| Servier Bio-Innovation LLC | Phase 2 | MTAP-deleted Solid Tumors | 61 |
| AstraZeneca | Phase 2 | APOL1-Mediated Kidney Disease | 63 |
| Ascendis Pharma A/S | Phase 2 | Achondroplasia | 25 |
| Atossa Therapeutics, Inc. | Phase 2 | Precocious Puberty, Gonadotropin-dependent | 6 |
| Teva Branded Pharmaceutical Products R&D LLC | Phase 2 | Celiac Disease | 50 |
| Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Non-small Cell Lung Cancer | 76 |
| Chengdu Anticancer Bioscience, Ltd. | Phase 2 | Advance Solid Tumors; Lymphoma, Non-Hodgkin | 150 |
| Genentech, Inc. | Phase 2 | Hepatocellular Carcinoma | 30 |
| Merck Sharp & Dohme LLC | Phase 2 | HIV-1; HIV Infection | 45 |
| Tiger Biosciences, LLC. | Phase 2 | Lower Extremity; Chronic Ulcers; Pressure Ulcer (PU); Venous Leg Ulcer (VLU); Wound Management | 30 |
| Incyte Corporation | Phase 2 | Unresectable Cholangiocarcinoma; Advanced/Metastatic Cholangiocarcinoma | 72 |
| Merck Sharp & Dohme LLC | Phase 2 | Noninfectious Intermediate, Posterior, or Panuveitis | 87 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 | Primary Membranous Nephropathy; Minimal Change Disease; Focal Segmental Glomerulosclerosis | 20 |
| Genmab | Phase 2 | Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma | 78 |
| AbbVie | Phase 2 | Forehead Lines | 84 |
| Zhejiang Yuejia Pharmaceuticals Co., Ltd. | Phase 2 | Diabetic Peripheral Neuropathic Pain (DPNP) | 196 |
| AmacaThera Inc. | Phase 2 | Bunionectomy; Bunion | 60 |
| H. Lundbeck A/S | Phase 2 | Adrenal Hyperplasia, Congenital | 45 |
| Kyowa Kirin Co., Ltd. | Phase 2 | Indolent B-cell Non-Hodgkin's Lymphoma | 61 |
| Urmila DIwekar | Phase 2 | Ivf | 100 |
| AstraZeneca | Phase 2 | Prostate Cancer | 6 |
| Friendi.fi Corporation | Phase 2 | Fall; Mild Cognitive Impairment (MCI); Aging | 300 |
| Genentech, Inc. | Phase 2 | Geographic Atrophy Secondary to Age-Related Macular Degeneration | 321 |
| LimmaTech Biologics AG | Phase 2 | Shigellosis | 97 |
| Merck Sharp & Dohme LLC | Phase 2 | HIV | 80 |
| XellSmart Therapeutics (Shanghai) Co., Ltd. | Phase 2 | Parkinson's Disease | 39 |
| Ipsen | Phase 2 | Melanoma; Head and Neck Squamous Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Solid Tumor | 36 |
| Ipsen | Phase 2 | Advanced Solid Tumor | 42 |
All ClinicalTrialStartPulse record reports